EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Silymarin in combination with hair follicle transplantation as a potential treatment for refractory vitiligo: A double‐blind randomized controlled trial

Amir Feily iD, Masoome Hosseinpour, Leila Samipour iD, Seyedeh Yasamin Parvar iD, Maryam Hadibarhaghtalab iD, MReza Goodarzian iD

Journal of Cosmetic Dermatology · 2024

DOI: 10.1111/jocd.16525 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cosmetic Dermatology, 2024. Verfasst von Amir Feily und 5 weiteren Autor:innen. Beteiligte Einrichtung: Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Vitiligo, Silymarin, Hair Follicle. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There is still no certain effective treatment for vitiligo as a common chronic skin disorder characterized by depigmented patches and loss of skin melanocytes.

Objectives

This study evaluates the efficacy of oral silymarin combined with hair follicle transplantation compared to follicle transplantation alone in the treatment of refractory vitiligo. Materials and Methods Twenty refractory vitiligo patients were enrolled in this randomized controlled clinical trial, following up for 3 months. One group underwent hair transplantation plus oral silymarin, while the other group underwent follicle transplantation alone. We assessed the progress with Vitiligo Extent Tensity Index ( VETI ) in both groups and the peri‐follicular pigmentation diameter was estimated monthly. The Friedman test for comparing two groups at the end and the Mann–Whitney test for comparing two groups during each month was used.

Results

The mean age was 30.22 (18–59) years, with the male to female ratio of 1:1. The decrease in the VETI and increase in the perifollicular pigmentation was statistically significant between silymarin and another group in monthly follow‐up ( p ‐value: 0.019, 0.019, and 0.035, respectively). Finally, the re‐pigmentation was notable in silymarin group ( p ‐value

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VitiligoSilymarinHair FollicleHumansFemaleMaleAdultYoung AdultMiddle AgedDouble-Blind MethodAdolescentCombined Modality TherapyTreatment OutcomeSkin PigmentationAdministration, Oral

Stichwörter der Autor:innen

Silybum marianumclinical trialmilk thistlesilymarinvitiligo

Substanzen

Silymarin

Autor:innen und Institutionen

  • Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Department of Otorhinolaryngology, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Molecular Dermatology Research Center, Dermatology Department, Shiraz University of Medical Sciences, Shiraz, Iran.

ORCID-Profile: Amir Feily, Leila Samipour, Seyedeh Yasamin Parvar, Maryam Hadibarhaghtalab, MReza Goodarzian

Zitieren

APA

Feily, A., Hosseinpour, M., Samipour, L., Parvar, S. Y., Hadibarhaghtalab, M., & Goodarzian, M. (2024). Silymarin in combination with hair follicle transplantation as a potential treatment for refractory vitiligo: A double‐blind randomized controlled trial. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.16525

Vancouver

Feily A, Hosseinpour M, Samipour L, Parvar SY, Hadibarhaghtalab M, Goodarzian M. Silymarin in combination with hair follicle transplantation as a potential treatment for refractory vitiligo: A double‐blind randomized controlled trial. Journal of Cosmetic Dermatology. 2024. doi:10.1111/jocd.16525

BibTeX
@article{Feily2024,
  author = {Feily, Amir and Hosseinpour, Masoome and Samipour, Leila and Parvar, Seyedeh Yasamin and Hadibarhaghtalab, Maryam and Goodarzian, MReza},
  title = {Silymarin in combination with hair follicle transplantation as a potential treatment for refractory vitiligo: A double‐blind randomized controlled trial},
  journal = {Journal of Cosmetic Dermatology},
  year = {2024},
  doi = {10.1111/jocd.16525}
}
Kostenlos starten →